This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Jun 16;357(9272):1898-9.

doi: 10.1016/S0140-6736(00)05087-X.

GUSTO V: the bottom line of fibrinolytic reperfusion therapy

Affiliations

PMID: 11425404
DOI: 10.1016/S0140-6736(00)05087-X

Comment

GUSTO V: the bottom line of fibrinolytic reperfusion therapy

F W Verheugt. Lancet. 2001.

. 2001 Jun 16;357(9272):1898-9.

doi: 10.1016/S0140-6736(00)05087-X.

Author

Affiliation

¹ Division of Cardiology, Heartcenter, University Medical Center St Radboud, 6525, Nijmegen, Netherlands. f.verheugt@cardio.azn.nl

PMID: 11425404
DOI: 10.1016/S0140-6736(00)05087-X

No abstract available

PubMed Disclaimer

Comment in

Lyse now, stent later: the grace of GRACIA.
Verheugt FW. Verheugt FW. Lancet. 2004 Sep 18-24;364(9439):1014-5. doi: 10.1016/S0140-6736(04)17072-4. Lancet. 2004. PMID: 15380948 No abstract available.

Comment on

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topol EJ; GUSTO V Investigators. Topol EJ, et al. Lancet. 2001 Jun 16;357(9272):1905-14. doi: 10.1016/s0140-6736(00)05059-5. Lancet. 2001. PMID: 11425410 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information